JP2015517525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517525A5 JP2015517525A5 JP2015512779A JP2015512779A JP2015517525A5 JP 2015517525 A5 JP2015517525 A5 JP 2015517525A5 JP 2015512779 A JP2015512779 A JP 2015512779A JP 2015512779 A JP2015512779 A JP 2015512779A JP 2015517525 A5 JP2015517525 A5 JP 2015517525A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- composition
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| US61/648,110 | 2012-05-17 | ||
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517525A JP2015517525A (ja) | 2015-06-22 |
| JP2015517525A5 true JP2015517525A5 (enExample) | 2016-06-30 |
| JP6234443B2 JP6234443B2 (ja) | 2017-11-22 |
Family
ID=48576527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512779A Active JP6234443B2 (ja) | 2012-05-17 | 2013-05-15 | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10004782B2 (enExample) |
| EP (1) | EP2849776B1 (enExample) |
| JP (1) | JP6234443B2 (enExample) |
| KR (2) | KR20150013838A (enExample) |
| CN (2) | CN118453592A (enExample) |
| AU (2) | AU2013262895A1 (enExample) |
| BR (1) | BR112014028622A2 (enExample) |
| CA (1) | CA2872021C (enExample) |
| EA (1) | EA201492109A1 (enExample) |
| ES (1) | ES2878001T3 (enExample) |
| HK (1) | HK1202458A1 (enExample) |
| IL (1) | IL235484A0 (enExample) |
| IN (1) | IN2014DN09554A (enExample) |
| MX (1) | MX360304B (enExample) |
| SG (2) | SG10201609644UA (enExample) |
| WO (1) | WO2013173417A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| CN118453592A (zh) | 2012-05-17 | 2024-08-09 | Vtv治疗有限责任公司 | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 |
| KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
| LT3804714T (lt) * | 2018-05-31 | 2025-03-10 | Hua Medicine (Shanghai) Ltd. | Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas |
| AU2019287437A1 (en) * | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| WO2021151251A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| AU2020451588A1 (en) * | 2020-06-04 | 2023-01-19 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CA3185834A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CN116194442A (zh) * | 2020-06-08 | 2023-05-30 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途 |
| CN121202809A (zh) * | 2020-06-08 | 2025-12-26 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
| CN115350268B (zh) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | 一种用于治疗糖尿病的制剂、微针及其制备工艺 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (enExample) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| US6660716B1 (en) * | 1999-06-21 | 2003-12-09 | Eli Lilly And Company | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| WO2005006614A1 (ja) * | 2003-07-14 | 2005-01-20 | Sony Corporation | 情報提供方法 |
| WO2005023766A1 (en) | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| JP2008502658A (ja) * | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
| US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
| KR20080024211A (ko) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
| BRPI0612996A2 (pt) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| EA018988B1 (ru) | 2008-05-16 | 2013-12-30 | Такеда Калифорния, Инк. | Активаторы глюкокиназы |
| JP5731196B2 (ja) | 2008-07-22 | 2015-06-10 | 株式会社クレハ | 末端ハロゲン基含量が低減されたポリアリーレンスルフィドの製造方法 |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| PL2419097T3 (pl) | 2009-04-16 | 2014-02-28 | Taisho Pharmaceutical Co Ltd | Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy |
| KR101190957B1 (ko) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| CN118453592A (zh) * | 2012-05-17 | 2024-08-09 | Vtv治疗有限责任公司 | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 |
| AU2014226292B2 (en) | 2013-03-04 | 2018-10-04 | Vtv Therapeutics Llc | Solid compositions comprising a glucokinase activator and methods of making and using the same |
| WO2014137797A2 (en) | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
-
2013
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/zh active Pending
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/xx unknown
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko not_active Ceased
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503539A5 (enExample) | ||
| JP2013529617A5 (enExample) | ||
| JP2016510795A5 (enExample) | ||
| Cornell | A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents | |
| JP2015520155A5 (enExample) | ||
| JP2018522843A5 (enExample) | ||
| JP6293897B2 (ja) | ネコ科動物の代謝異常の治療 | |
| JP5260303B2 (ja) | 筋肉損失の治療のための方法 | |
| RU2443691C2 (ru) | Мочевинные активаторы глюкокиназы | |
| Mittermayer et al. | Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| JP2015120698A5 (enExample) | ||
| EA200800198A1 (ru) | Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида | |
| AR078517A1 (es) | Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos para su tratamiento y sus usos | |
| HRP20191713T1 (hr) | Pripravci, uporabe i metode za liječenje metaboličkih poremećaja i bolesti | |
| JP2013532644A5 (enExample) | ||
| KR20190122806A (ko) | 조합 치료요법용 약학 조성물 | |
| NO20091229L (no) | Kombinasjonsterapi med SGLT-2 inhibitorer og deres farmasoytiske sammensetninger | |
| JP2011503152A5 (enExample) | ||
| WO2007112069A3 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
| JP2017508794A5 (enExample) | ||
| WO2012097428A1 (en) | Compounds and pharmaceutical compositions for uses in diabetes | |
| JP2014525454A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| JP2014503593A5 (enExample) |